Goodwin Procter advised Minovia Therapeutics on the deal. Minovia Therapeutics announced its worldwide strategic collaboration and license agreement with Astellas Pharma (TSE: 4503) to research, develop, and...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here